Wang Pei-Li, Zhang Lei, Wang Shao-Li, Yang Qiao-Ning, Gao Zhu-Ye, Du Jian-Peng, Zhang Da-Wu, Fu Chang-Geng, Gu Feng, Xu Hao, Li Li-Zhi, Wang Cheng-Long, Shi Da-Zhuo
Institute of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Department of Gastroenterology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Chin J Integr Med. 2017 Oct;23(10):740-746. doi: 10.1007/s11655-016-2608-9. Epub 2016 Oct 24.
To evaluate the prognosis effect of Chinese herbal medicines (CHMs) for benefiting qi and activating blood circulation adjunctive to conventional treatment in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI).
A total of 702 patients with ACS who underwent PCI were enrolled and randomly assigned to receive conventional treatment plus CHMs for benefiting qi and activating blood circulation (treatment group, 351 cases) or conventional treatment alone (control group, 351 cases) for 6 months. Six months later, all patients received conventional treatment alone. Follow-ups were scheduled at 6th, 12th, 18th, 24th month after enrollment in April 2008, and the final follow-up visit was during September 2011 and November 2011. The primary endpoint was the composite of cardiac death, nonfatal myocardial infarction or revascularization (PCI or coronary artery bypass grafting); and the secondary endpoint was the composite of re-admission for ACS, congestive heart failure, nonfatal stroke or other thrombus events.
A total of 621 (88.59%) patients completed 35.4±3.8 months follow-up, while 80 (11.41%) patients withdrew from the trial (41 in the treatment group and 39 in the control group). The incidence of primary endpoint was 5.7% (20 patients) in the treatment group versus 10.86% (38 patients) in the control group [relative risk (RR): 0.53; 95% confidence interval (CI): 0.30, 0.88; P=0.013; absolute risk reduction (ARR):-0.052, 95% CI: -0.06, 0.01]. The incidence of secondary endpoint was 5.98% (21 patients) in the treatment group versus 10.28% (36 patients) in control group (RR: 0.58, 95% CI: 0.33, 0.97, P=0.037; ARR: -0.043, 95% CI: 0.06, 0.01). Most of the primary and secondary endpoints were occurred in 18 months (84.50% in the treatment group versus 78.10% in the control group).
CHMs for benefiting qi and activating blood circulation adjunctive to conventional treatment improved clinical outcomes for patients with ACS after PCI in long-term follow-up.
评价益气活血中药辅助常规治疗对急性冠状动脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后预后的影响。
共纳入702例行PCI的ACS患者,随机分为接受常规治疗加益气活血中药治疗组(治疗组,351例)或单纯常规治疗组(对照组,351例),治疗6个月。6个月后,所有患者均接受单纯常规治疗。于2008年4月入组后第6、12、18、24个月安排随访,末次随访时间为2011年9月至2011年11月。主要终点为心源性死亡、非致死性心肌梗死或血运重建(PCI或冠状动脉搭桥术)的复合终点;次要终点为因ACS再次入院、充血性心力衰竭、非致死性卒中或其他血栓事件的复合终点。
共621例(88.59%)患者完成了35.4±3.8个月的随访,80例(11.41%)患者退出试验(治疗组41例,对照组39例)。治疗组主要终点发生率为5.7%(20例),对照组为10.86%(38例)[相对危险度(RR):0.53;95%置信区间(CI):0.30,0.88;P = 0.013;绝对危险度降低率(ARR):-0.052,95%CI:-0.06,0.01]。治疗组次要终点发生率为5.98%(21例),对照组为10.28%(36例)(RR:0.58,95%CI:0.33,0.97,P = 0.037;ARR:-0.043,95%CI:0.06,0.01)。大部分主要终点和次要终点事件发生在18个月内(治疗组为84.50%,对照组为78.10%)。
益气活血中药辅助常规治疗可改善ACS患者PCI术后长期随访的临床结局。